In my case, Cigna refused to cover Mounjaro at the lowest dose, which forced me to increase it on corporate timing, not my own or my doctors
Ozempic The diabetes drug Ozempic is one of the most commonly prescribed and heavily used GLP-1 receptor agonists on the market
Conflict of interest Flynn McGuire, Riley Martinez, Annika Lenz, Lee Skinner, and Dan Cushman declare that they have no conflict of interest
Nowhile berberine may offer mild benefits for blood sugar or metabolism, it does not work like GLP-1 medications and is not comparable in effectiveness
In clinical trials, patients lost significantly more weight on Tirzepatide than on any single-receptor GLP-1
Returning to our Part D dashboard, we see their collective dominance in Medicare Part D in 2019, as nearly 20 million prescriptions were dispensed at a pre-rebate cost of $12 billion in the program during that time, as shown in Figure 5 (note that the unit costs of Xarelto looks a little high in comparison, because it is dosed one unit per day as opposed to Eliquis and Pradaxa, which are both dosed at two units per day
